MADISON, Wis. / Feb 01, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2023 financial results after the close of the U.S. financial markets on February 21, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Fourth quarter 2023 webcast & conference call details
Date: | Wednesday, February 21, 2024 |
Time: | 5 p.m. ET |
Webcast: | The live webcast can be accessed at www.exactsciences.com |
Telephone: | Domestic callers, dial 888-330-2384 |
International callers, dial +1 240-789-2701 | |
| Access code for both domestic and international callers: 4437608 |
A replay of the webcast will be available at www.exactsciences.com. The webcast, conference call, and replay are open to all interested parties.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
| Last Trade: | US$51.91 |
| Daily Change: | -1.41 -2.64 |
| Daily Volume: | 1,673,065 |
| Market Cap: | US$9.790B |
July 09, 2025 May 22, 2025 May 01, 2025 April 29, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
